Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Papillomavirus Infections | 37 | 2024 | 260 | 8.100 |
Why?
|
Early Detection of Cancer | 57 | 2024 | 409 | 7.760 |
Why?
|
Uterine Cervical Neoplasms | 38 | 2024 | 294 | 7.670 |
Why?
|
Papillomavirus Vaccines | 22 | 2022 | 58 | 7.150 |
Why?
|
Carcinoma, Hepatocellular | 19 | 2023 | 405 | 3.270 |
Why?
|
Liver Neoplasms | 19 | 2023 | 770 | 2.800 |
Why?
|
Mammography | 15 | 2021 | 465 | 2.630 |
Why?
|
Vaccination | 12 | 2022 | 269 | 2.380 |
Why?
|
Safety-net Providers | 10 | 2019 | 37 | 2.370 |
Why?
|
Patient Acceptance of Health Care | 14 | 2022 | 253 | 2.260 |
Why?
|
Parents | 9 | 2023 | 285 | 2.210 |
Why?
|
Breast Neoplasms | 24 | 2021 | 2976 | 2.190 |
Why?
|
Health Behavior | 11 | 2023 | 183 | 2.160 |
Why?
|
Mass Screening | 30 | 2022 | 631 | 2.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 15 | 2021 | 525 | 1.990 |
Why?
|
Alphapapillomavirus | 8 | 2022 | 45 | 1.910 |
Why?
|
Colorectal Neoplasms | 18 | 2022 | 970 | 1.850 |
Why?
|
Liver Cirrhosis | 16 | 2023 | 305 | 1.750 |
Why?
|
Surveys and Questionnaires | 19 | 2024 | 2590 | 1.650 |
Why?
|
Population Surveillance | 8 | 2018 | 217 | 1.640 |
Why?
|
Texas | 24 | 2024 | 108 | 1.600 |
Why?
|
Middle Aged | 84 | 2024 | 25649 | 1.500 |
Why?
|
Female | 118 | 2024 | 45686 | 1.490 |
Why?
|
Delivery of Health Care | 10 | 2023 | 432 | 1.450 |
Why?
|
Adult | 72 | 2024 | 26303 | 1.360 |
Why?
|
Humans | 147 | 2024 | 88480 | 1.300 |
Why?
|
Neoplasms | 11 | 2023 | 3003 | 1.260 |
Why?
|
Papanicolaou Test | 10 | 2022 | 39 | 1.250 |
Why?
|
Vaginal Smears | 13 | 2023 | 70 | 1.210 |
Why?
|
Adolescent | 35 | 2024 | 9141 | 1.200 |
Why?
|
Practice Patterns, Physicians' | 7 | 2023 | 597 | 1.130 |
Why?
|
Language | 5 | 2019 | 154 | 1.130 |
Why?
|
Aged | 54 | 2024 | 18904 | 1.110 |
Why?
|
Oropharyngeal Neoplasms | 3 | 2023 | 132 | 1.080 |
Why?
|
Attitude to Health | 7 | 2019 | 221 | 1.040 |
Why?
|
Motivation | 5 | 2021 | 295 | 0.980 |
Why?
|
Electronic Health Records | 4 | 2018 | 340 | 0.950 |
Why?
|
Health Services Needs and Demand | 3 | 2023 | 103 | 0.950 |
Why?
|
Cancer Survivors | 3 | 2021 | 94 | 0.940 |
Why?
|
Papillomaviridae | 11 | 2023 | 155 | 0.910 |
Why?
|
HIV Infections | 4 | 2021 | 827 | 0.910 |
Why?
|
Young Adult | 25 | 2023 | 6193 | 0.870 |
Why?
|
Information Seeking Behavior | 2 | 2013 | 14 | 0.860 |
Why?
|
Anniversaries and Special Events | 1 | 2022 | 14 | 0.830 |
Why?
|
Health Promotion | 5 | 2019 | 160 | 0.820 |
Why?
|
Occult Blood | 6 | 2018 | 16 | 0.810 |
Why?
|
Patient Education as Topic | 4 | 2018 | 356 | 0.800 |
Why?
|
Health Equity | 1 | 2023 | 85 | 0.790 |
Why?
|
Persuasive Communication | 2 | 2021 | 8 | 0.770 |
Why?
|
Head and Neck Neoplasms | 3 | 2023 | 1057 | 0.770 |
Why?
|
United States | 32 | 2024 | 6877 | 0.740 |
Why?
|
Registries | 8 | 2015 | 754 | 0.720 |
Why?
|
Intimate Partner Violence | 1 | 2020 | 27 | 0.720 |
Why?
|
Male | 50 | 2024 | 41953 | 0.710 |
Why?
|
Guideline Adherence | 5 | 2024 | 226 | 0.710 |
Why?
|
Urban Population | 4 | 2022 | 223 | 0.690 |
Why?
|
Data Accuracy | 2 | 2018 | 31 | 0.680 |
Why?
|
Cross-Sectional Studies | 10 | 2023 | 1688 | 0.680 |
Why?
|
Gonorrhea | 1 | 2019 | 19 | 0.680 |
Why?
|
Chlamydia Infections | 1 | 2019 | 26 | 0.680 |
Why?
|
Self-Examination | 1 | 2018 | 5 | 0.660 |
Why?
|
Syphilis | 1 | 2019 | 30 | 0.660 |
Why?
|
Survivors | 3 | 2015 | 233 | 0.640 |
Why?
|
Postal Service | 6 | 2023 | 17 | 0.630 |
Why?
|
Professional-Family Relations | 1 | 2018 | 52 | 0.610 |
Why?
|
Sexually Transmitted Diseases | 1 | 2019 | 96 | 0.600 |
Why?
|
Self Report | 3 | 2016 | 294 | 0.580 |
Why?
|
Colposcopy | 4 | 2024 | 16 | 0.570 |
Why?
|
Aged, 80 and over | 17 | 2022 | 6713 | 0.560 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 299 | 0.560 |
Why?
|
Child | 14 | 2023 | 7081 | 0.560 |
Why?
|
Anus Neoplasms | 3 | 2021 | 35 | 0.550 |
Why?
|
Pilot Projects | 5 | 2023 | 865 | 0.550 |
Why?
|
Communication | 3 | 2023 | 452 | 0.550 |
Why?
|
Health Education | 2 | 2015 | 101 | 0.520 |
Why?
|
Immunization Programs | 3 | 2013 | 24 | 0.520 |
Why?
|
Public Health Surveillance | 1 | 2015 | 21 | 0.510 |
Why?
|
Psychological Theory | 2 | 2015 | 22 | 0.500 |
Why?
|
Health Literacy | 1 | 2016 | 71 | 0.490 |
Why?
|
Reproducibility of Results | 13 | 2021 | 2744 | 0.480 |
Why?
|
Veterans | 4 | 2008 | 83 | 0.460 |
Why?
|
Interviews as Topic | 5 | 2021 | 333 | 0.450 |
Why?
|
Pregnancy in Adolescence | 2 | 2023 | 25 | 0.430 |
Why?
|
Uterine Cervical Dysplasia | 2 | 2023 | 32 | 0.430 |
Why?
|
Colonoscopy | 4 | 2017 | 274 | 0.430 |
Why?
|
Qualitative Research | 4 | 2017 | 285 | 0.410 |
Why?
|
Risk Factors | 14 | 2023 | 5439 | 0.410 |
Why?
|
Prevalence | 5 | 2023 | 1248 | 0.400 |
Why?
|
Mothers | 1 | 2012 | 142 | 0.390 |
Why?
|
Medically Uninsured | 3 | 2022 | 60 | 0.390 |
Why?
|
Pandemics | 5 | 2023 | 760 | 0.380 |
Why?
|
Intention | 3 | 2019 | 50 | 0.380 |
Why?
|
Physician-Patient Relations | 1 | 2016 | 622 | 0.370 |
Why?
|
Contraception | 4 | 2024 | 92 | 0.370 |
Why?
|
Ambulatory Care Facilities | 1 | 2011 | 111 | 0.370 |
Why?
|
Socioeconomic Factors | 8 | 2018 | 577 | 0.360 |
Why?
|
Behavioral Risk Factor Surveillance System | 2 | 2013 | 14 | 0.360 |
Why?
|
Social Class | 3 | 2023 | 134 | 0.360 |
Why?
|
Feasibility Studies | 3 | 2023 | 771 | 0.330 |
Why?
|
Social Media | 2 | 2023 | 87 | 0.330 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2020 | 59 | 0.320 |
Why?
|
Patient Selection | 5 | 2021 | 689 | 0.320 |
Why?
|
Quality of Life | 4 | 2023 | 1647 | 0.320 |
Why?
|
Healthcare Disparities | 4 | 2023 | 394 | 0.320 |
Why?
|
Poverty | 5 | 2022 | 179 | 0.310 |
Why?
|
Rural Population | 2 | 2018 | 143 | 0.290 |
Why?
|
Patient Navigation | 2 | 2016 | 13 | 0.280 |
Why?
|
Primary Health Care | 3 | 2017 | 350 | 0.280 |
Why?
|
Patient Compliance | 3 | 2021 | 228 | 0.280 |
Why?
|
Residence Characteristics | 4 | 2016 | 194 | 0.280 |
Why?
|
Health Services Accessibility | 6 | 2021 | 418 | 0.270 |
Why?
|
Cost-Benefit Analysis | 4 | 2023 | 453 | 0.270 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 479 | 0.260 |
Why?
|
Retrospective Studies | 10 | 2020 | 8869 | 0.250 |
Why?
|
Health Care Surveys | 6 | 2013 | 281 | 0.250 |
Why?
|
Chi-Square Distribution | 4 | 2012 | 360 | 0.250 |
Why?
|
Anxiety | 3 | 2023 | 307 | 0.240 |
Why?
|
Follow-Up Studies | 4 | 2020 | 3653 | 0.240 |
Why?
|
Caregivers | 2 | 2023 | 156 | 0.240 |
Why?
|
Practice Guidelines as Topic | 6 | 2024 | 1038 | 0.240 |
Why?
|
Precision Medicine | 2 | 2020 | 407 | 0.240 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2022 | 73 | 0.240 |
Why?
|
Clinical Trials as Topic | 3 | 2022 | 1142 | 0.230 |
Why?
|
Research | 2 | 2018 | 250 | 0.230 |
Why?
|
Minority Groups | 3 | 2016 | 140 | 0.230 |
Why?
|
Counseling | 2 | 2024 | 160 | 0.230 |
Why?
|
Community-Institutional Relations | 1 | 2023 | 29 | 0.230 |
Why?
|
Asthma | 2 | 2022 | 973 | 0.230 |
Why?
|
Ultrasonography | 4 | 2021 | 703 | 0.230 |
Why?
|
Personal Autonomy | 2 | 2016 | 116 | 0.230 |
Why?
|
Pregnancy | 6 | 2023 | 2994 | 0.220 |
Why?
|
Research Design | 7 | 2020 | 594 | 0.220 |
Why?
|
Intrauterine Devices | 1 | 2023 | 28 | 0.220 |
Why?
|
Contraceptive Agents, Female | 1 | 2023 | 31 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2023 | 1165 | 0.220 |
Why?
|
Depression | 3 | 2022 | 499 | 0.210 |
Why?
|
Nutrition Surveys | 1 | 2023 | 111 | 0.210 |
Why?
|
California | 5 | 2017 | 143 | 0.210 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2022 | 3 | 0.210 |
Why?
|
Meningococcal Vaccines | 1 | 2022 | 3 | 0.210 |
Why?
|
Cohort Studies | 7 | 2020 | 2833 | 0.210 |
Why?
|
Adolescent Behavior | 1 | 2023 | 108 | 0.200 |
Why?
|
Vaccines | 1 | 2023 | 82 | 0.200 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2021 | 8 | 0.200 |
Why?
|
Longitudinal Studies | 4 | 2021 | 1048 | 0.190 |
Why?
|
Gynecology | 1 | 2023 | 129 | 0.190 |
Why?
|
Social Sciences | 1 | 2020 | 5 | 0.190 |
Why?
|
Behavioral Sciences | 1 | 2020 | 3 | 0.190 |
Why?
|
Behavioral Research | 1 | 2020 | 10 | 0.190 |
Why?
|
Self Care | 2 | 2022 | 164 | 0.190 |
Why?
|
Prospective Studies | 4 | 2023 | 4268 | 0.190 |
Why?
|
Risk Assessment | 7 | 2021 | 2285 | 0.180 |
Why?
|
Depressive Disorder, Major | 1 | 2022 | 165 | 0.180 |
Why?
|
Perception | 2 | 2019 | 178 | 0.180 |
Why?
|
Anti-HIV Agents | 1 | 2023 | 154 | 0.180 |
Why?
|
Educational Status | 4 | 2023 | 191 | 0.180 |
Why?
|
Reminder Systems | 3 | 2016 | 17 | 0.180 |
Why?
|
Vulnerable Populations | 2 | 2020 | 80 | 0.180 |
Why?
|
Pre-Exposure Prophylaxis | 1 | 2023 | 143 | 0.180 |
Why?
|
DNA, Viral | 1 | 2020 | 265 | 0.180 |
Why?
|
Insurance, Health | 4 | 2018 | 160 | 0.180 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2019 | 39 | 0.170 |
Why?
|
Syphilis Serodiagnosis | 1 | 2019 | 5 | 0.170 |
Why?
|
Hospice Care | 2 | 2019 | 40 | 0.170 |
Why?
|
Factor Analysis, Statistical | 3 | 2019 | 113 | 0.170 |
Why?
|
Advance Directives | 2 | 2019 | 64 | 0.170 |
Why?
|
Precancerous Conditions | 1 | 2021 | 200 | 0.170 |
Why?
|
Uterine Neoplasms | 1 | 2023 | 242 | 0.170 |
Why?
|
alpha-Fetoproteins | 2 | 2016 | 45 | 0.170 |
Why?
|
Exercise | 2 | 2013 | 322 | 0.170 |
Why?
|
Urban Health | 1 | 2019 | 56 | 0.170 |
Why?
|
Antibodies, Viral | 1 | 2020 | 306 | 0.170 |
Why?
|
Program Evaluation | 2 | 2017 | 302 | 0.160 |
Why?
|
Advance Care Planning | 1 | 2019 | 43 | 0.160 |
Why?
|
Decision Making | 2 | 2018 | 661 | 0.160 |
Why?
|
Research Support as Topic | 2 | 2015 | 82 | 0.160 |
Why?
|
Vaccination Refusal | 1 | 2018 | 10 | 0.160 |
Why?
|
Age Factors | 5 | 2018 | 1860 | 0.150 |
Why?
|
Sex Characteristics | 1 | 2020 | 320 | 0.150 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2019 | 491 | 0.150 |
Why?
|
Palliative Care | 2 | 2019 | 264 | 0.150 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2020 | 388 | 0.150 |
Why?
|
Washington | 1 | 2017 | 49 | 0.150 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 409 | 0.150 |
Why?
|
Medical Oncology | 1 | 2021 | 375 | 0.140 |
Why?
|
Health Services Research | 2 | 2014 | 137 | 0.140 |
Why?
|
DNA | 1 | 2023 | 1308 | 0.140 |
Why?
|
Rural Health Services | 1 | 2016 | 17 | 0.140 |
Why?
|
Medically Underserved Area | 1 | 2016 | 27 | 0.140 |
Why?
|
Decision Support Techniques | 1 | 2018 | 165 | 0.140 |
Why?
|
Discriminant Analysis | 1 | 2016 | 67 | 0.140 |
Why?
|
Hormones | 1 | 2017 | 141 | 0.140 |
Why?
|
Tape Recording | 1 | 2016 | 19 | 0.140 |
Why?
|
Ultrasonography, Doppler | 1 | 2016 | 85 | 0.140 |
Why?
|
Nitriles | 1 | 2017 | 160 | 0.140 |
Why?
|
Triazoles | 1 | 2017 | 100 | 0.140 |
Why?
|
Literacy | 1 | 2016 | 2 | 0.140 |
Why?
|
Regression Analysis | 3 | 2017 | 594 | 0.140 |
Why?
|
Attitude of Health Personnel | 3 | 2023 | 642 | 0.140 |
Why?
|
Medicaid | 2 | 2017 | 228 | 0.140 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 44 | 0.140 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 156 | 0.140 |
Why?
|
Tamoxifen | 1 | 2017 | 168 | 0.140 |
Why?
|
Attitude to Death | 1 | 2016 | 36 | 0.130 |
Why?
|
Hospitals, Community | 1 | 2015 | 32 | 0.130 |
Why?
|
Ambulatory Care | 1 | 2017 | 186 | 0.130 |
Why?
|
Medication Adherence | 1 | 2017 | 134 | 0.130 |
Why?
|
Hospitals, University | 1 | 2015 | 195 | 0.130 |
Why?
|
Adenocarcinoma | 1 | 2022 | 1184 | 0.130 |
Why?
|
Adenoma | 1 | 2017 | 243 | 0.130 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 510 | 0.120 |
Why?
|
Internship and Residency | 1 | 2024 | 1036 | 0.120 |
Why?
|
Community-Based Participatory Research | 1 | 2014 | 36 | 0.120 |
Why?
|
T-Lymphocytes | 1 | 2021 | 1220 | 0.120 |
Why?
|
Specimen Handling | 3 | 2020 | 101 | 0.120 |
Why?
|
Terminal Care | 1 | 2016 | 137 | 0.120 |
Why?
|
Biomarkers | 1 | 2020 | 1757 | 0.120 |
Why?
|
Quality Improvement | 1 | 2018 | 443 | 0.120 |
Why?
|
Time Factors | 3 | 2018 | 5308 | 0.120 |
Why?
|
Psychometrics | 3 | 2019 | 328 | 0.120 |
Why?
|
Clinical Competence | 2 | 2024 | 779 | 0.110 |
Why?
|
ROC Curve | 1 | 2016 | 773 | 0.110 |
Why?
|
Physicians | 1 | 2021 | 684 | 0.110 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 759 | 0.110 |
Why?
|
Sexual Behavior | 2 | 2023 | 307 | 0.110 |
Why?
|
Nuclear Family | 2 | 2023 | 91 | 0.110 |
Why?
|
Contraceptive Agents | 2 | 2023 | 20 | 0.110 |
Why?
|
Genetic Counseling | 1 | 2013 | 101 | 0.110 |
Why?
|
Infant | 1 | 2019 | 3113 | 0.110 |
Why?
|
Lung Neoplasms | 2 | 2022 | 2335 | 0.100 |
Why?
|
Child, Preschool | 1 | 2019 | 3671 | 0.100 |
Why?
|
Gammapapillomavirus | 1 | 2011 | 1 | 0.100 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2011 | 6 | 0.100 |
Why?
|
Health Personnel | 2 | 2018 | 209 | 0.100 |
Why?
|
Beneficence | 1 | 2011 | 34 | 0.100 |
Why?
|
Social Behavior | 1 | 2014 | 297 | 0.100 |
Why?
|
Family Characteristics | 1 | 2011 | 49 | 0.100 |
Why?
|
Biomarkers, Tumor | 1 | 2020 | 1520 | 0.100 |
Why?
|
Estrogen Replacement Therapy | 1 | 2011 | 45 | 0.100 |
Why?
|
Confidentiality | 1 | 2011 | 77 | 0.100 |
Why?
|
Models, Statistical | 1 | 2015 | 575 | 0.100 |
Why?
|
Research Personnel | 1 | 2011 | 70 | 0.100 |
Why?
|
Data Collection | 2 | 2013 | 374 | 0.100 |
Why?
|
Sex Factors | 2 | 2012 | 1063 | 0.100 |
Why?
|
Immunization | 1 | 2011 | 160 | 0.100 |
Why?
|
Logistic Models | 3 | 2013 | 1204 | 0.090 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 858 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2012 | 383 | 0.090 |
Why?
|
Cognition | 1 | 2014 | 577 | 0.090 |
Why?
|
Anxiety Disorders | 2 | 2021 | 151 | 0.090 |
Why?
|
Genetic Testing | 1 | 2013 | 536 | 0.080 |
Why?
|
Choice Behavior | 1 | 2010 | 160 | 0.080 |
Why?
|
Odds Ratio | 3 | 2017 | 685 | 0.080 |
Why?
|
Informed Consent | 1 | 2011 | 273 | 0.080 |
Why?
|
Incidence | 3 | 2020 | 1588 | 0.080 |
Why?
|
Sigmoidoscopy | 1 | 2008 | 36 | 0.080 |
Why?
|
Income | 1 | 2008 | 81 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2020 | 1982 | 0.070 |
Why?
|
Hysterectomy | 1 | 2008 | 150 | 0.070 |
Why?
|
Analysis of Variance | 2 | 2008 | 902 | 0.070 |
Why?
|
Patient Participation | 2 | 2021 | 224 | 0.070 |
Why?
|
Social Marketing | 1 | 2006 | 10 | 0.070 |
Why?
|
Pamphlets | 1 | 2006 | 14 | 0.070 |
Why?
|
Health Status | 1 | 2008 | 368 | 0.070 |
Why?
|
Self Disclosure | 1 | 2006 | 32 | 0.070 |
Why?
|
Focus Groups | 2 | 2017 | 164 | 0.070 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 2405 | 0.070 |
Why?
|
Insurance Coverage | 2 | 2016 | 119 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 1 | 2006 | 62 | 0.060 |
Why?
|
Prognosis | 3 | 2020 | 3749 | 0.060 |
Why?
|
Demography | 1 | 2005 | 181 | 0.060 |
Why?
|
Guidelines as Topic | 1 | 2005 | 159 | 0.060 |
Why?
|
Diagnostic Self Evaluation | 1 | 2023 | 12 | 0.060 |
Why?
|
Telephone | 2 | 2016 | 35 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 1704 | 0.050 |
Why?
|
Philadelphia | 1 | 2022 | 18 | 0.050 |
Why?
|
Fellowships and Scholarships | 1 | 2024 | 119 | 0.050 |
Why?
|
Likelihood Functions | 2 | 2019 | 252 | 0.050 |
Why?
|
Respiratory Function Tests | 1 | 2022 | 140 | 0.050 |
Why?
|
Immunization Schedule | 1 | 2022 | 21 | 0.050 |
Why?
|
Child Abuse, Sexual | 1 | 2002 | 19 | 0.050 |
Why?
|
Travel | 1 | 2022 | 72 | 0.050 |
Why?
|
Life Change Events | 1 | 2002 | 48 | 0.050 |
Why?
|
Bias | 1 | 2022 | 130 | 0.050 |
Why?
|
Human Papillomavirus DNA Tests | 1 | 2021 | 2 | 0.050 |
Why?
|
Complementarity Determining Regions | 1 | 2021 | 24 | 0.050 |
Why?
|
Proof of Concept Study | 1 | 2021 | 39 | 0.050 |
Why?
|
Child Abuse | 1 | 2002 | 82 | 0.050 |
Why?
|
Conflict of Interest | 1 | 2021 | 67 | 0.050 |
Why?
|
Human papillomavirus 16 | 1 | 2020 | 38 | 0.050 |
Why?
|
Stakeholder Participation | 1 | 2020 | 21 | 0.050 |
Why?
|
Mass Vaccination | 1 | 2020 | 9 | 0.050 |
Why?
|
Spain | 1 | 2020 | 33 | 0.050 |
Why?
|
Suicide, Attempted | 1 | 2002 | 131 | 0.050 |
Why?
|
Population Health | 1 | 2020 | 33 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2020 | 8151 | 0.050 |
Why?
|
Ethics, Research | 1 | 2020 | 52 | 0.040 |
Why?
|
Mental Health | 1 | 2021 | 174 | 0.040 |
Why?
|
Biomedical Research | 1 | 2004 | 389 | 0.040 |
Why?
|
Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.040 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2020 | 48 | 0.040 |
Why?
|
Pediatrics | 1 | 2024 | 351 | 0.040 |
Why?
|
Secondary Prevention | 1 | 2020 | 163 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2016 | 994 | 0.040 |
Why?
|
Age of Onset | 1 | 2020 | 311 | 0.040 |
Why?
|
Living Wills | 1 | 2019 | 4 | 0.040 |
Why?
|
Cost of Illness | 1 | 2020 | 148 | 0.040 |
Why?
|
Developing Countries | 1 | 2020 | 74 | 0.040 |
Why?
|
Patient Preference | 1 | 2020 | 108 | 0.040 |
Why?
|
Public Health | 1 | 2020 | 135 | 0.040 |
Why?
|
Medicare | 1 | 2023 | 420 | 0.040 |
Why?
|
Europe | 1 | 2020 | 314 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 126 | 0.040 |
Why?
|
Patient Reported Outcome Measures | 1 | 2020 | 189 | 0.040 |
Why?
|
Machine Learning | 1 | 2021 | 242 | 0.040 |
Why?
|
Cervix Uteri | 1 | 2018 | 70 | 0.040 |
Why?
|
Ovary | 1 | 2020 | 261 | 0.040 |
Why?
|
Professional Practice Gaps | 1 | 2018 | 1 | 0.040 |
Why?
|
Vaccination Coverage | 1 | 2018 | 5 | 0.040 |
Why?
|
Information Systems | 1 | 2018 | 29 | 0.040 |
Why?
|
Health Surveys | 2 | 2008 | 239 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2022 | 2019 | 0.040 |
Why?
|
Intestinal Polyps | 1 | 2017 | 26 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2017 | 150 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 477 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2018 | 112 | 0.040 |
Why?
|
Interinstitutional Relations | 1 | 2016 | 29 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2016 | 93 | 0.040 |
Why?
|
Motivational Interviewing | 1 | 2016 | 20 | 0.040 |
Why?
|
Osteocalcin | 1 | 1996 | 26 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2016 | 157 | 0.030 |
Why?
|
Feces | 1 | 2018 | 326 | 0.030 |
Why?
|
Transcriptome | 1 | 2021 | 619 | 0.030 |
Why?
|
Osteoblasts | 1 | 1996 | 96 | 0.030 |
Why?
|
Needs Assessment | 1 | 2016 | 158 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 1425 | 0.030 |
Why?
|
Primary Prevention | 1 | 2015 | 79 | 0.030 |
Why?
|
Biopsy | 1 | 2018 | 1187 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2018 | 1712 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 447 | 0.030 |
Why?
|
Personnel Selection | 1 | 2014 | 60 | 0.030 |
Why?
|
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 5 | 0.030 |
Why?
|
Small-Area Analysis | 1 | 2013 | 8 | 0.030 |
Why?
|
Multilevel Analysis | 1 | 2013 | 24 | 0.030 |
Why?
|
Communication Barriers | 1 | 2012 | 29 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2015 | 180 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2013 | 235 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 1996 | 553 | 0.030 |
Why?
|
Hepatitis C, Chronic | 1 | 2013 | 127 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 1996 | 1156 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2015 | 1790 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2013 | 1019 | 0.020 |
Why?
|
Survival Rate | 1 | 2014 | 1881 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2013 | 365 | 0.020 |
Why?
|
Publication Bias | 1 | 2010 | 13 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 226 | 0.020 |
Why?
|
Medicine | 1 | 2010 | 90 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2013 | 514 | 0.020 |
Why?
|
Self Efficacy | 1 | 2008 | 54 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 431 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2008 | 837 | 0.020 |
Why?
|
Georgia | 1 | 2002 | 35 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 1996 | 68 | 0.010 |
Why?
|
Nucleotides | 1 | 1996 | 97 | 0.010 |
Why?
|
Hot Temperature | 1 | 1996 | 207 | 0.010 |
Why?
|
HeLa Cells | 1 | 1996 | 505 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1996 | 1056 | 0.010 |
Why?
|
Up-Regulation | 1 | 1996 | 729 | 0.010 |
Why?
|
Binding Sites | 1 | 1996 | 1113 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 1996 | 956 | 0.010 |
Why?
|
Cell Differentiation | 1 | 1996 | 1513 | 0.010 |
Why?
|
Rats | 1 | 1996 | 4034 | 0.010 |
Why?
|
Mutation | 1 | 1996 | 4096 | 0.000 |
Why?
|
Animals | 1 | 1996 | 27186 | 0.000 |
Why?
|